- Home
- KTF vs VCEL Comparison
KTF vs VCEL Comparison
Compare KTF & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KTF
- VCEL
- Stock Information
- Founded
- KTF 1988
- VCEL 1989
- Country
- KTF United States
- VCEL United States
- Employees
- KTF N/A
- VCEL N/A
- Industry
- KTF Finance Companies
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KTF Finance
- VCEL Health Care
- Exchange
- KTF Nasdaq
- VCEL Nasdaq
- Market Cap
- KTF 349.0M
- VCEL 2.1B
- IPO Year
- KTF N/A
- VCEL 1997
- Fundamental
- Price
- KTF $8.85
- VCEL $40.15
- Analyst Decision
- KTF
- VCEL Strong Buy
- Analyst Count
- KTF 0
- VCEL 8
- Target Price
- KTF N/A
- VCEL $62.00
- AVG Volume (30 Days)
- KTF 103.3K
- VCEL 430.8K
- Earning Date
- KTF 01-01-0001
- VCEL 07-31-2025
- Dividend Yield
- KTF 3.54%
- VCEL N/A
- EPS Growth
- KTF N/A
- VCEL 521.85
- EPS
- KTF 0.39
- VCEL 0.05
- Revenue
- KTF N/A
- VCEL $238,541,000.00
- Revenue This Year
- KTF N/A
- VCEL $23.03
- Revenue Next Year
- KTF N/A
- VCEL $24.52
- P/E Ratio
- KTF $23.10
- VCEL $705.61
- Revenue Growth
- KTF N/A
- VCEL 14.80
- 52 Week Low
- KTF $7.40
- VCEL $37.39
- 52 Week High
- KTF $9.12
- VCEL $63.00
- Technical
- Relative Strength Index (RSI)
- KTF 48.39
- VCEL 44.33
- Support Level
- KTF $8.71
- VCEL $40.53
- Resistance Level
- KTF $8.93
- VCEL $43.57
- Average True Range (ATR)
- KTF 0.06
- VCEL 1.62
- MACD
- KTF 0.02
- VCEL -0.16
- Stochastic Oscillator
- KTF 63.64
- VCEL 28.65
About KTF DWS Municipal Income Trust
DWS Municipal Income Trust is a closed-ended fixed income mutual fund launched and managed by Deutsche Investment Management Americas, Inc. The company invests in the fixed income markets of the United States. The fund invests in investment-grade tax-exempt municipal securities which are exempt from federal income tax. The fund benchmarks the performance of its portfolio against the Barclays Municipal Bond Index. The Fund invests in various states, such as Texas, Florida, Pennsylvania, Illinois, and California.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.